https://doi.org/10.4081/aiua.2023.11171
TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting
Published: February 22, 2023
Abstract Views: 904
PDF: 496
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
To the Editor,
Bladder cancer (BCa) is the second most common cancer in urological clinical practice, after prostate adenocarcinoma. Usually occurs in patients between 60 and 70 years old, three times more frequently in men than women. About 75% of bladder cancer are pTa or pT1, even more frequently considering a population younger than 40 years old. Early detection is of paramount importance since allows to find tumors when they are still superficial and therefore with a better prognosis.
Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6):4-34. doi:10.1016/J.UROLOGY.2005.07.062
DOI: https://doi.org/10.1016/j.urology.2005.07.062
Malinaric R, Mantica G, Balzarini F, Terrone C, Maffezzini M. Extraperitoneal cystectomy with ureterocutaneostomy derivation in fragile patients - should it be performed more often? Arch Ital Urol Androl. 2022 Jun 29;94(2):144-149. doi: 10.4081/aiua.2022.2.144. PMID: 35775336.
DOI: https://doi.org/10.4081/aiua.2022.2.144
Maffezzini M, Fontana V, Pacchetti A, et al. Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients. Arch Ital Urol Androl. 2021 Mar 18;93(1):15-20. doi: 10.4081/aiua.2021.1.15. PMID: 33754602.
DOI: https://doi.org/10.4081/aiua.2021.1.15
EAU Guidelines on Non-muscle-invasive Bladder Cancer - DIAGNOSIS - Uroweb. Accessed September 14, 2022. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/diagnosis
Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247-256. doi:10.1016/J.EURURO.2009.04.038
DOI: https://doi.org/10.1016/j.eururo.2009.04.038
Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209-216. doi:10.1046/J.1464-410X.2001.02306.X
DOI: https://doi.org/10.1046/j.1464-410x.2001.02306.x
Gregg JR, McCormick B, Wang L, et al. Short term complications from transurethral resection of bladder tumor. Can J Urol. 2016 Apr;23(2):8198-203. PMID: 27085823.
Chen J, Zhao Y, Wang S, et al. Green-light laser en bloc resection for primary non-muscle-invasive bladder tumor versus transurethral electroresection: A prospective, nonrandomized two-center trial with 36-month follow-up. Lasers Surg Med. 2016;48(9):859-865. doi:10.1002/LSM.22565
DOI: https://doi.org/10.1002/lsm.22565
Zhang XR, Feng C, Zhu WD, et al. Two Micrometer Continuous-Wave Thulium Laser Treating Primary Non-Muscle-Invasive Bladder Cancer: Is It Feasible? A Randomized Prospective Study. Photomed Laser Surg. 2015;33(10):517-523. doi:10.1089/PHO.2015.3913
DOI: https://doi.org/10.1089/pho.2015.3913
Xu Y, Guan W, Chen W, et al. Comparing the treatment outcomes of potassium-titanyl-phosphate laser vaporization and transurethral electroresection for primary nonmuscle-invasive bladder cancer: A prospective, randomized study. Lasers Surg Med. 2015;47(4):306-311. doi:10.1002/LSM.22342
DOI: https://doi.org/10.1002/lsm.22342
Chen X, Liao J, Chen L, et al. En bloc transurethral resection with 2-micron continuous-wave laser for primary non-muscle-invasive bladder cancer: a randomized controlled trial. World J Urol. 2015;33(7):989-995. doi:10.1007/S00345-014-1342-1
DOI: https://doi.org/10.1007/s00345-014-1342-1
Yu J, Zheng J. Comparative efficacy and safety of transurethral laser surgery with holmium laser, KTP laser, 2-micron laser or thulium laser for the treatment of non-muscle invasive bladder carcinoma: a protocol of network meta-analysis. BMJ Open. 2021;11(12). doi:10.1136/BMJOPEN-2021-055840
DOI: https://doi.org/10.1136/bmjopen-2021-055840
Leonardi R, Calarco A, Falcone L, Grasso V, Frisenda M, Tufano A, Viscuso P, Rossi A, Memeo L. Endoscopic laser en bloc removal of bladder tumor. Surgical radicality and improvement of the pathological diagnostic accuracy. Arch Ital Urol Androl. 2022 Jun 29;94(2):134-137. doi: 10.4081/aiua.2022.2.134. PMID: 35775334.
DOI: https://doi.org/10.4081/aiua.2022.2.134
Sawazaki H, Arai Y, Ito Y, et al. Expression of L-Type Amino Acid Transporter 1 is a Predictive Biomarker of Intravesical Recurrence in Patients with Non-Muscle Invasive Bladder Cancer. Res Rep Urol. 2021 Aug 21;13:603-611. doi: 10.2147/RRU.S326249. PMID: 34458203; PMCID: PMC8387640.
DOI: https://doi.org/10.2147/RRU.S326249
EAU Guidelines 2022 on Urological Infections. Edn. presented at the EAU Annual Congress Amsterdam, the Netherlands 2022.ISBN 978-94-92671-16-5
Leonardi R, Bellinzoni P, Broglia L, et al. Hospital care in Departments defined as COVID-free: A proposal for a safe hospitalization protecting healthcare professionals and patients not affected by COVID-19. Arch Ital Urol Androl. 2020 Apr 24;92(2). doi: 10.4081/aiua.2020.2.67. PMID: 32597101.
DOI: https://doi.org/10.4081/aiua.2020.2.67
Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21(18):1315-30. doi: 10.1007/BF03262330. PMID: 14750899.
DOI: https://doi.org/10.1007/BF03262330
Meeks JJ, Herr HW. Office-based management of nonmuscle invasive bladder cancer. Urol Clin North Am. 2013 Nov;40(4):473-9. doi: 10.1016/j.ucl.2013.07.004. Epub 2013 Aug 6. PMID: 24182970.
DOI: https://doi.org/10.1016/j.ucl.2013.07.004
O'Neil BB, Lowrance WT. Office-based Bladder Tumor Fulguration and Surveillance: Indications and Techniques. Urol Clin North Am. 2013 May;40(2):175-82. doi: 10.1016/j.ucl.2013.01.007. Epub 2013 Feb 15. PMID: 23540776.
DOI: https://doi.org/10.1016/j.ucl.2013.01.007
Donat SM, North A, Dalbagni G, Herr HW. Efficacy of office fulguration for recurrent low grade papillary bladder tumors less than 0.5 cm. J Urol. 2004 Feb;171(2 Pt 1):636-9. doi: 10.1097/01.ju.0000103100.22951.5e. PMID: 14713776.
DOI: https://doi.org/10.1097/01.ju.0000103100.22951.5e
Pedersen GL, Erikson MS, Mogensen K, Rosthøj S, Hermann GG. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol. 2022 Sep 1:S0302-2838(22)02564-7. doi: 10.1016/j.eururo.2022.08.012. Epub ahead of print. PMID: 36058804.
DOI: https://doi.org/10.1016/j.eururo.2022.08.012
How to Cite
Leonardi, R., Vecco, F., Iacona, G., Calarco, A., & Mantica, G. (2023). TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting. Archivio Italiano Di Urologia E Andrologia, 95(1). https://doi.org/10.4081/aiua.2023.11171
Copyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.